XRN Stock Analysis: Chiron Real Estate | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 486m USD | 12M Return: -1% | US37954A3032 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.97M
Qual. Beats: 0
Rev. Trend: 79.8%
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Chiron Real Estate Inc. (NYSE: XRN) is a healthcare-focused real estate investment trust (REIT) that invests in properties serving the healthcare sector, aiming to create value at the intersection of care delivery, capital, and real estate. The company was established in 2011 and is incorporated in Maryland, with a small-cap market capitalization of $490M USD and an IPO date of June 29, 2016.
As a Health Care REIT under the GICS classification, Chiron operates within a sector that typically owns and leases property types such as medical office buildings, hospitals, senior living facilities, skilled nursing properties, and life science/lab space. These REITs generally earn revenue through long-term triple-net or modified gross leases with healthcare operators, providing landlords with relatively stable, contractually defined rental income tied to essential care-delivery assets.
- Aging population tailwind boosts medical office demand
- Interest rate cuts lift healthcare REIT valuations
- Hospital tenant credit risk pressures occupancy and rents
| Net Income: 57.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA -4.81 > 1.0 |
| NWC/Revenue: -434.7% < 20% (prev -11.98%; Δ -422.7% < -1%) |
| CFO/TA 0.05 > 3% & CFO 75.1m > Net Income 57.9m |
| Net Debt (639.7m) to EBITDA (158.4m): 4.04 < 3 |
| Current Ratio: 0.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.2m) vs 12m ago -1.05% < -2% |
| Gross Margin: 0.39% > 18% (prev 40.20%; Δ -39.81% > 0.5%) |
| Asset Turnover: 11.75% > 50% (prev 11.43%; Δ 0.32% > 0%) |
| Interest Coverage Ratio: 2.74 > 6 (EBIT TTM 98.7m / Interest Expense TTM 36.0m) |
| A: -0.50 (Total Current Assets 13.7m - Total Current Liabilities 695.1m) / Total Assets 1.37b |
| B: -0.22 (Retained Earnings -303.7m / Total Assets 1.37b) |
| C: 0.07 (EBIT TTM 98.7m / Avg Total Assets 1.33b) |
| D: 0.96 (Book Value of Equity 656.9m / Total Liabilities 687.7m) |
| Altman-Z'' = -2.48 = D |
| DSRI: 0.77 (Receivables 6.79m/8.29m, Revenue 156.8m/148.3m) |
| GMI: 103.7 (GM 40.20% / 0.39%) |
| AQI: 1.00 (AQ_t 0.97 / AQ_t-1 0.97) |
| SGI: 1.06 (Revenue 156.8m / 148.3m) |
| TATA: -0.01 (NI 57.9m - CFO 75.1m) / TA 1.37b) |
| Beneish M = 89.83 (Cap -4..+1) = D |
As of October 17, 2026, the stock is trading at USD 30.34 with a total of 208,652 shares traded. Over the past week, the price has changed by -9.68%, over one month by -14.47%, over three months by -19.26% and over the past year by -0.96%.
Current recommended Stop Loss: 29.20 (which is 3.8% or 1.4 ATR below the current price).
Chiron Real Estate has received a consensus analysts rating of 3.73. Therefore, it is recommended to hold XRN.
- StrongBuy: 3
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 38.6 | 27.1% |
P/E Trailing = 9.0134
P/E Forward = 714.2857
P/S = 3.166
P/B = 1.0782
P/EG = 5.0864
Revenue TTM = 156.8m USD
EBIT TTM = 98.7m USD
EBITDA TTM = 158.4m USD
Long Term Debt = 633.1m USD (from longTermDebt, last quarter)
Short Term Debt = 658k USD (from shortTermDebt, last quarter)
Debt = 650.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.4m
Net Debt = 639.7m USD (calculated: Debt 650.3m - CCE 10.7m)
Enterprise Value = 1.13b USD (485.5m + Debt 650.3m - CCE 10.7m)
Interest Coverage Ratio = 2.74 (Ebit TTM 98.7m / Interest Expense TTM 36.0m)
EV/FCF = -8.56x (Enterprise Value 1.13b / FCF TTM -131.5m)
FCF Yield = -11.68% (FCF TTM -131.5m / Enterprise Value 1.13b)
FCF Margin = -83.86% (FCF TTM -131.5m / Revenue TTM 156.8m)
Net Margin = 36.96% (Net Income TTM 57.9m / Revenue TTM 156.8m)
Gross Margin = 0.39% ((Revenue TTM 156.8m - Cost of Revenue TTM 156.2m) / Revenue TTM)
Gross Margin QoQ = -2.11% (prev -2.21%)
Tobins Q-Ratio = 0.82 (Enterprise Value 1.13b / Total Assets 1.37b)
Interest Expense / Debt = 5.53% (Interest Expense 36.0m / Debt 650.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 78.0m (EBIT 98.7m * (1 - 21.00%))
Current Ratio = 0.02 (Total Current Assets 13.7m / Total Current Liabilities 716.0m)
Debt / Equity = 0.99 (Debt 650.3m / totalStockholderEquity, last quarter 656.9m)
Debt / EBITDA = 4.04 (Net Debt 639.7m / EBITDA 158.4m)
Debt / FCF = -4.87 (negative FCF - burning cash) (Net Debt 639.7m / FCF TTM -131.5m)
Total Stockholder Equity = 538.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.34% (Net Income 57.9m / Total Assets 1.37b)
RoE = 10.77% (Net Income TTM 57.9m / Total Stockholder Equity 538.1m)
RoCE = 8.43% (EBIT 98.7m / Capital Employed (Equity 538.1m + L.T.Debt 633.1m))
RoIC = 5.72% (NOPAT 78.0m / Invested Capital 1.36b)
WACC = 5.31% (E(485.5m)/V(1.14b) * Re(6.57%) + D(650.3m)/V(1.14b) * Rd(5.53%) * (1-Tc(0.21)))
Discount Rate = 6.57% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.95 | Cagr: 105.3%
[DCF] Fair Price = unknown (Cash Flow -131.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.58 | # QB: 0
Revenue Correlation: 79.82 | Revenue CAGR: 5.25% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.70 | Chg30d=+17.65% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=3.22 | Chg30d=+12.98% | Revisions=+0% | GrowthEPS=+453.9% | GrowthRev=+4.2%
EPS next Year (2027-12-31): EPS=-3.18 | Chg30d=+22.36% | Revisions=-25% | GrowthEPS=-540.8% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: -40% (up=0, down=2)